Updates in Adjuvant Therapy in Pancreatic Cancer: Gemcitabine and Beyond

  • Joshua Richter Yale University School of Medicine, New Haven, CT, USA
  • Muhammad Wasif Saif Yale University School of Medicine, New Haven, CT, USA
Keywords: Chemotherapy, Adjuvant, Combined Modality Therapy, erlotinib, gemcitabine, Pancreatic Neoplasms


Pancreatic cancer represents the 4th leading cause of cancer deaths in the United States. Surgical resection remains the only potential curative approach. However, given the notion of a high recurrence rate, adjuvant therapy is needed to offset this risk. The 2010 American Society of Oncology Gastrointestinal Cancers Symposium offered new insights into optimized approaches towards adjuvant therapy of pancreatic cancer. Abstracts focusing on the role of targeted therapy utilizing erlotinib or GI-4000 in combination with gemcitabine (Abstracts #224 and #229) were presented. Subbiah, et al. presented a retrospective analysis comparing systemic chemotherapy versus chemoradiotherapy (Abstract #230) in the adjuvant setting. In addition, a data driven prediction tool to help predict which patients would be able to complete a course of adjuvant therapy in order to select out those who may alternative approaches (Abstract #236) was also presented. The authors summarize these findings presented at the 2010 ASCO Gastrointestinal Cancers Symposium, January 22-24, 2010, Orlando, FL, USA.

Image: Chemical structure of gemcitabine (Author: Calvero, Wikimedia Comons)


Download data is not yet available.


Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics, 2009. CA Cancer J Clin 2009; 59:225-49. [PMID 19474385] (FULL TEXT: http://caonline.amcancersoc.org/cgi/content/full/59/4/225)

Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004; 363:1049-57. [PMID 15051286] (FULL TEXT: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(04)15841-8/fulltext)

Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007; 297:267-77. [PMID 17227978] (FULL TEXT: http://jama.ama-assn.org/cgi/reprint/297/3/267)

Bao PQ, Ramanathan RK, Moser AJ, Bahary N, Lembersky BC, Bartlett DL, et al. Phase II trial of adjuvant gemcitabine and erlotinib for resected pancreatic cancer. 2010 ASCO Gastrointestinal Cancers Symposium. Abstract No. 224. (FULL TEXT: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=72&abstractID=2348)

Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25:1960-6. [PMID 17452677] (FULL TEXT: http://jco.ascopubs.org/cgi/content/full/25/15/1960)

Richards DA, Muscarella P, Ritch PS, Fisher WE, Flynn PJ, Whiting SH, et al. A randomized phase II adjuvant trial of resected patients with ras mutation bearing pancreas cancer treated with GI-4000 and gemcitabine or gemcitabine alone: A safety analysis of the first 100 treated patients. 2010 ASCO Gastrointestinal Cancers Symposium. Abstract No. 229. (FULL TEXT: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=72&abstractID=1361)

Hruban RH, van Mansfeld AD, Offerhaus GJ, van Weering DH, Allison DC, Goodman SN, et al. k-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 1993; 143:545-54. [PMID 8342602] (FULL TEXT: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1887038/pdf/amjpathol00068-0227.pdf)

Subbiah S, Aldoss I, Gonsalves W, Tashi T, Al-Howaidi I, Silberstein PT. Adjuvant chemotherapy versus chemoradiation therapy in resectable pancreatic cancer: Retrospective analysis from the VA Central Cancer Registry (VACCR) database. 2010 ASCO Gastrointestinal Cancers Symposium. Abstract No. 230. (FULL TEXT: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=72&abstractID=2402)

Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999; 230:776-82. [PMID 10615932] (FULL TEXT: http://journals.lww.com/annalsofsurgery/pages/articleviewer.aspx?year=1999&issue=12000&article=00006&type=abstract)

Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350:1200-10. [PMID 15028824] (FULL TEXT: http://content.nejm.org/cgi/content/full/350/12/1200)

National Comprehensive Cancer Network. Pancreatic Adenocarcinoma V.1.2009. NCCN Clinical Practice Guidelines in Oncology. (FULL TEXT: http://www.nccn.org/professionals/physician_gls/PDF/pancreatic.pdf)

Smith JK, Ng S, Simons JP, Zhou Z, Shah SA, McDade TP, et al. Adjuvant therapy for resectable pancreatic cancer: A simple prediction rule. 2010 ASCO Gastrointestinal Cancers Symposium. Abstract No. 236. (FULL TEXT: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=72&abstractID=2188)

Lepisto AJ, Moser AJ, Zeh H, Lee K, Bartlett D, McKolanis JR, et al. A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther 2008; 6:955-64. [PMID 19129927] (FULL TEXT: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2614325/?tool=pubmed)

Rong Y, Jin D, Wu W, Lou W, Wang D, Kuang T, Ni X, Qin X. Induction of protective and therapeutic anti-pancreatic cancer immunity using a reconstructed MUC1 DNA vaccine. BMC Cancer 2009; 9:191. [PMID 19534821] (FULL TEXT: http://www.biomedcentral.com/1471-2407/9/191)

Saif MW. Controversies in the adjuvant treatment of pancreatic adenocarcinoma. JOP. J Pancreas (Online) 2007; 8:545-52. [PMID 17873458] (FULL TEXT: http://www.joplink.net/prev/200709/16.html)

Chemical structure of gemcitabine
How to Cite
RichterJ., & SaifM. (2010). Updates in Adjuvant Therapy in Pancreatic Cancer: Gemcitabine and Beyond. JOP. Journal of the Pancreas, 11(2), 144-147. https://doi.org/10.6092/1590-8577/3848
Highlights from the “2010 ASCO Gastrointestinal Cancers Symposium”. Orlando, FL, USA. January 22-24, 2010